Evaluation of Hodgkin lymphoma cases and determination of prognostic factors;Hodgkin lenfoma olgularının retrospektif deǧerlendirilmesi ve prognostik faktörlerin saptanması

Turk Onkoloji Dergisi

Volumn 26, Issue 3, 2011, Pages 108-114

  Şeker, Mesut ^a   Meng, Alperen ^b   Bilici, Ahmet ^b   Ustaalioǧlu, Bala Başak ^b   Kefeli, Umut ^b   Özşeker, Naciye Işik ^c   Mayadaǧli, Alparslan ^c   Salepci, Taflan ^b   Gümüş, Mahmut ^b  

^a Tekirda Devlet Hastanesi   (Turkey)

^b Haydarpasa Egitim Hastanesi   (Turkey)

^c Radyasyon Onkolojisi Anabilim Dali   (Turkey)

Author keywords

Hodgkin lymphoma; Prognostic factor

Indexed keywords

LACTATE DEHYDROGENASE;

DISEASE FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

EID: 80755185303     PISSN: 13007467     EISSN: None     Source Type: Journal    
DOI: 10.5505/tjoncol.2011.630     Document Type: Review

References (13)

1. Knowles MD. Neoplastic hematopathology. 2nd ed. New York: Lippincott Williams & Wilkins; 2001. P 610-80.
2. Straathof KC, Bollard CM, Rooney CM, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist 2003;8(1):83-98.
3. Jaffe ES, Haris NL, Stelin H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. Lyon: IARC Pres; 2001.
4. Lanzkowsky P. Manual of pediatric hematology and oncology. 4th ed. Burlington, MA: Academic Press; 2005. p. 453-90.
5. Kiliçkap S. Hacettepe Üniversitesi Onkoloji Enstitüsü Medikal Onkoloji Bölümü'nde takip edilen Hodgkin lenfoma olgulari{dotless}ni{dotless}n klinikopatolojik özellikleri. Hacettepe Üniversitesi Onkoloji Enstitüsü Medikal Onkoloji Bilim Dali{dotless} Tezi, Ankara: 2009.
6. Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epide-Epidemiology and etiology of Hodgkin's lymphoma. Ann Oncol 2002;13:147-52.
7. Stein RS. Hodgkin's disease. In: Lee RG, Foerster J, Lukens J, et al. (editors). Wintrobe's clinical hematology. 10th ed. Egypt. Mass Pub; 1999. p. 2538-71.
8. Rosen PJ, Lavey RS, Haskell CM. Hodgkin's disease In: Haskell CM, editor. Cancer treatment. 4th ed. Philadelphia: W.B. Saunder Company; 1995. p. 951-79.
9. Kaplan HS. Hodgkin disease. Harvard University, Cambridge, MA: 1980.
10. Portlock CS, Glick J. Hodgkin's disease. In: Hofmann R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, et al. (editors). Hematology: Basic Principles and Practice. 3rd ed. New York: Churchill Livingstone; 2000. p. 1241-62.
11. Crnkovich MJ, Leopold K, Hoppe RT, Mauch PM. Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol 1987;5(7):1041-9.
12. Yildiz F, Zengin N, Engin H, Güllü I, Barista I, Caglar M, et al. Prospective study of combined modality treatment or radiotherapy alone in the management of earlystage adult Hodgkin's disease. Int J Radiat Oncol Biol Phys 2004;60(3):839-46.
13. Coşkun HŞ, Er Ö, Eser B, Çetin M, Altinbaş M, Soyuer S ve ark. Erken evre Hodgkin hastaliǧi: Erciyes Üniversitesi deneyimi. Erciyes Tip Dergisi 2002;24(3):120-5.